Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.32 |
| ▸ | CES2 | O00748 | 3/20 | 0.31 |
| ▸ | CES1 | P23141 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.30 |
| ▸ | LSS | P48449 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8026449 | 1.00 | TSHR (0.36) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL7398423 | 1.00 | TSHR (0.36) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL6673774 | 0.98 | TSHR (0.38) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL8590656 | 0.98 | TSHR (0.32) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL15572200 | 0.98 | TSHR (0.38) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL1258373 | 0.98 | TSHR (0.38) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL11260353 | 0.95 | TSHR (0.33) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL1527590 | 0.91 | CYP1A2 (0.31) | — | |
| SCHEMBL9876888 | 0.91 | TSHR (0.33) | TSHRTHRBGNAI3GNAO1GNAI1 | |
| SCHEMBL5469877 | 0.88 | LMNA (0.30) | TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256023-A1 | DERIVED MULTIPLE ALLOGENEIC PROTEINS PARACRINE SIGNALING (d-MAPPS) REGENERATIVE BIOLOGICS PLATFORM TECHNOLOGY ADJUVANT THERAPY FOR THE PREVENTION AND TARGETED TREATMENT OF CANCER AND OTHER DISORDERS | MAM Holdings of West Florida, L.L.C. | 2023-08-17 | — | — | US | disclosed |
| US-20230041289-A1 | COMPOSITIONS AND METHODS FOR ENHANCING OR TREATING FEMALE SEXUAL RESPONSE | T K INC APS (DK) | 2023-02-09 | — | — | US | disclosed |
| US-10441530-B2 | Skin penetration enhancing systems for polar drugs | AmDerma Pharmaceuticals, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180161389-A1 | R-SPONDIN AGONIST-MEDIATED HAIR GROWTH | ULIXA, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180078495-A1 | Skin Penetration Enhancing Systems for Polar Drugs | DERMACT PHARMACEUTICAL, INC. | 2018-03-22 | — | — | US | disclosed |
| EP-2769976-B1 | HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF | BEIJING KONRUNS PHARMACEUTICAL CO LTD (CN) | 2017-08-02 | — | — | EP | disclosed |
| US-9333209-B2 | Compositions for increasing hair growth | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-05-10 | — | — | US | disclosed |
| US-9186318-B2 | Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD (CN) | 2015-11-17 | — | — | US | disclosed |
| US-20150005291-A1 | Compositions for Increasing Hair Growth | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-01-01 | — | — | US | disclosed |
| EP-2769976-A1 | HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF | Beijing Konruns Pharmaceutical Co., Ltd. (CN) | 2014-08-27 | — | — | EP | disclosed |
| US-20040202739-A1 | Compositions and methods for treating female sexual response | SEMPRAE LABORATORIES, INC. | 2004-10-14 | — | — | US | disclosed |
| US-6737084-B2 | Compositions and methods for enhancing or treating female sexual response | QUALILIFE | 2004-05-18 | — | — | US | disclosed |
| US-6465442-B2 | Topical application of muscarinic and opioid agents for treatment of tinnitus | EL KHOURY GEORGE F (US) | 2002-10-15 | — | — | US | disclosed |
| US-20020034557-A1 | Compositions and methods for treating female sexual response | SEMPRAE LABORATORIES, INC. | 2002-03-21 | — | — | US | disclosed |
| US-20020010191-A1 | Topical application of muscarinic and opioid agents for treatment of tinnitus | EL KHOURY GEORGE F (US) | 2002-01-24 | — | — | US | disclosed |
| US-6262063-B1 | ADMINISTERING AN OPIOID AGENT WHICH ACTS ON OPIATE RECEPTORS WITHOUT DELIVERY INTO THE SYSTEMIC CIRCULATION OR TO THE CENTRAL NERVOUS SYSTEM, WITH THE PROVISO THAT SAID AGENT IS NOT DEXTROMETHORPHAN. | EL KHOURY GEORGE F (US) | 2001-07-17 | — | — | US | disclosed |
| US-6143278-A | TOPICAL ADMINISTRATION OF OPIOID ANALGESIC AGENT IN ADMIXTURE WITH SKIN OR MUCOSAL SPECIFIC PENETRATION ENHANCER TO PRODUCE LOCALIZED ANALGESIC EFFECT IN SKIN OR MUCOSAL TISSUE WITHOUT TRANSDERMAL MIGRATION OF OPIOD AGENT | ELKHOURY GEORGE F (US) | 2000-11-07 | — | — | US | disclosed |
| US-6011022-A | Topical application of muscarinic analgesic drugs such as neostigmine | EL KHOURY GEORGE F (US) | 2000-01-04 | — | — | US | disclosed |
| US-5994330-A | Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions | EL KHOURY GEORGES F (US) | 1999-11-30 | — | — | US | disclosed |
| US-4422970-A | ALKYLATION OF AZACYCLOHEPTAN-2-ONE, QUATERNARY AMMONIUM PHASE TRANSFER CATALYST | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078495-A1 | Skin Penetration Enhancing Systems for Polar Drugs | ABCB11, KCNK5, KCNQ5 | TSHR 4735/4885THRB 4542/4885GNAI3 2394/4885 |
| US-10441530-B2 | Skin penetration enhancing systems for polar drugs | ABCB11, KCNK5, KCNQ5 | TSHR 4735/4885THRB 4542/4885GNAI3 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.